Hudson Bay Capital Management LP Sells 60,425 Shares of BioMarin Pharmaceutical Inc. $BMRN

Hudson Bay Capital Management LP decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 10.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 526,420 shares of the biotechnology company’s stock after selling 60,425 shares during the quarter. Hudson Bay Capital Management LP owned about 0.27% of BioMarin Pharmaceutical worth $28,937,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. V Square Quantitative Management LLC purchased a new position in BioMarin Pharmaceutical during the second quarter valued at $25,000. Rise Advisors LLC bought a new stake in BioMarin Pharmaceutical during the first quarter worth about $30,000. Brooklyn Investment Group raised its stake in BioMarin Pharmaceutical by 2,250.0% during the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 540 shares during the last quarter. Hantz Financial Services Inc. increased its position in shares of BioMarin Pharmaceutical by 480.2% during the second quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 874 shares in the last quarter. Finally, Employees Retirement System of Texas purchased a new position in BioMarin Pharmaceutical in the 2nd quarter worth approximately $58,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Trading Up 0.6%

Shares of NASDAQ:BMRN opened at $53.31 on Friday. BioMarin Pharmaceutical Inc. has a 12-month low of $50.76 and a 12-month high of $73.51. The company has a market cap of $10.24 billion, a PE ratio of 20.04, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30. The stock has a 50 day moving average of $53.72 and a 200 day moving average of $55.77. The company has a current ratio of 4.83, a quick ratio of 3.10 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.20). The firm had revenue of $776.13 million during the quarter, compared to the consensus estimate of $782.42 million. BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.91 earnings per share. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. As a group, equities research analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Wall Street Analysts Forecast Growth

BMRN has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their target price on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Sanford C. Bernstein decreased their target price on BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a research report on Monday, November 3rd. Stifel Nicolaus reaffirmed a “hold” rating and set a $61.00 price target (down previously from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. Finally, Wolfe Research reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Sixteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $88.61.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.